Production of monoclonal antibodies based on the CIBEX expression system
The therapeutic efficacy of monoclonal antibodies (MAb) strongly depends on their target antigen specificity and the structure of N-glycan at the FC-region of an IgG antibody. Antibody glycosylation is a key parameter in the optimization of antibody therapeutics. Depending on the expression host, glycosylation pattern of the expressed MAb can be significantly different and highly heterogenous. The unique and very homogenous N-glycosylation of Ciliates make it the ideal expression system to produce antibodies that elicit their effector function mainly via ADCC (antibody dependent cell-mediated cytotoxicity).
Based on the anti-cancer monoclonal antibody rituximab, Cilian was able to demonstrate a significantly enhanced ADCC function, which is attributed to the unique N-linked glycosylation. This means, that a ciliate based expression of ADCC-mediating antibodies offers a route to large-scale production of MAbs with enhanced effector function properties.